Skip to content

ΕτικέταOpdivo

Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer

Tally another win for Bristol-Myers Squibb’s immunotherapy combination. Wednesday, the New Jersey drugmaker said its Opdivo-Yervoy pairing grabbed an FDA approval in patients with rare colon cancers that have progressed despite other … Continue Reading Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer

Merck’s Keytruda continues its string of blockbuster results, but BMS’ Opdivo still leads in sales

At the American Society of Clinical Oncology (ASCO) annual meeting over the weekend, Merck’s Keytruda continued its winning streak. In data presented at the meeting, the cancer immunotherapy was shown … Continue Reading Merck’s Keytruda continues its string of blockbuster results, but BMS’ Opdivo still leads in sales

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual … Continue Reading ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?